Home / Conditions / Osteoarthritis

Osteoarthritis: when insurers say no, reviewers often say yes

In 1,019 published external-review decisions involving osteoarthritis, independent physician reviewers overturned the insurer’s denial 76.6% of the time.

Published decisions
1,019
2001–2026
Overturned
76.6%
781 denials reversed

Most-fought treatments for osteoarthritis

What insurers denied — and how those fights ended.
TreatmentDecisionsOverturned
Viscosupplementation136
82.4%
Euflexxa Injections95
95.8%
Monovisc Injection36
97.2%
Synvisc Injections35
77.1%
Supartz Injections34
70.6%
Euflexxa Injection Series31
100%
Synvisc One Injection29
93.1%
Synvisc-one Injection28
92.9%
Orthovisc Injections24
62.5%
Durolane Injection23
100%
Monovisc Injections21
95.2%
Synvisc21
47.6%
Synvisc One18
55.6%
Hyaluronan Injections16
93.8%
Orthovisc16
56.2%
Synvisc-one14
100%
Synvisc One Injections13
69.2%
Durolane Injections13
100%
How to use this in your appeal

These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for osteoarthritis was denied, the published record says the denial is worth fighting.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for osteoarthritis? 76.6% won.

Explain my denial — free